{
    "clinical_study": {
        "@rank": "164637", 
        "arm_group": {
            "arm_group_label": "JUV\u00c9DERM VOLIFT\u2122", 
            "arm_group_type": "Experimental", 
            "description": "All subjects receiving treatment with JUV\u00c9DERM VOLIFT\u2122"
        }, 
        "brief_summary": {
            "textblock": "A prospective, open-label, multi-center, observational, post-market study evaluating\n      JUV\u00c9DERM VOLIFT\u2122 for the correction of moderate to severe nasolabial folds"
        }, 
        "brief_title": "Post-Market Study of JUV\u00c9DERM VOLIFT\u2122 With Lidocaine for the Correction of Nasolabial Folds", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate to Severe Nasolabial Folds", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 years of age or older\n\n          -  Have 2 fully visible, approximately symmetrical nasolabial folds and has severity\n             scores of 2 or 3 on the 5-point photographic nasolabial fold severity scale (range\n             0-4) for both nasolabial folds, as judged by the Investigator\n\n          -  Have a reasonable expectation for correction by injection via deep dermis, as\n             described in the protocol\n\n          -  Agree to refrain from undergoing other anti-wrinkle/volumizing treatments in the\n             lower two-thirds of the face (below the orbital rim) for the duration of the study\n\n          -  Understand and be willing to follow all aspects of the study protocol and have signed\n             and dated the Informed Consent prior to any study-related procedures being performed\n\n          -  Be in good health as in the opinion of the Investigator\n\n        Exclusion Criteria:\n\n          -  Has undergone cosmetic facial procedures (e.g., face lift or other surgeries) which\n             may alter the appearance of the nasolabial fold area\n\n          -  Cosmetic injections in the lower two-thirds of the face (below the orbital rim),\n             within 6 months prior to entry in the study, or be planning to undergo any of these\n             procedures at any time during the study.  NOTE:  Prior treatment with HA fillers\n             and/or collagen is allowed, provided the treatment was administered more than 6\n             months prior to study entry\n\n          -  Has undergone volumizing of the mid/lower face within 9 months prior to study entry\n\n          -  Has ever received semi-permanent fillers or permanent facial implants (e.g., calcium\n             hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate, silicone, expanded\n             poly-tetrafluoroethylene) anywhere in the lower face (below the orbital rim), or be\n             planning to be implanted with any of these products at any time during the study\n\n          -  Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to lidocaine\n             (an any amide-based anesthetics), HA products, or Streptococcal protein, or be\n             planning to undergo a desensitization therapy during the term of the study\n\n          -  Be a pregnant female, lactating, or planning to become pregnant at any time during\n             the study\n\n          -  Be a female of childbearing potential not using a reliable means of contraception\n\n          -  Have received any investigational product within 30 days prior to study enrollment or\n             be planning to participate in another investigation during the course of this study\n\n          -  Suffer from an uncontrolled personality disorder (e.g., body dysmorphia, depression)\n\n          -  Have a history of  or currently suffer from autoimmune disease (e.g., rheumatoid\n             arthritis, Crohn's disease)\n\n          -  Have a history of streptococcal disease (e.g., strep throat or rheumatic fever with\n             or without heart complications)\n\n          -  Have a history of skin cancer\n\n          -  Suffer from porphyria\n\n          -  Have epilepsy, which is not controlled by anti-epilepsy therapy\n\n          -  Current cutaneous inflammatory and/or infectious processes (e.g., acne, herpes)\n\n          -  Have a history of treatment with interferon\n\n          -  Be on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or have taken\n             non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other\n             substances known to increase coagulation time (e.g., herbal supplements with garlic\n             or ginkgo biloba) within 10 days of undergoing study device injection.  NOTE: Study\n             device injection may be delayed as necessary to accommodate this 10-day period\n\n          -  Be on a concurrent regimen of high doses of lidocaine (more than 400 mg) which may\n             cause acute toxic reactions\n\n          -  Be on a concurrent regimen of other local anesthetics structurally related to\n             amide-type local anesthetics\n\n          -  Have impaired cardiac conduction, severely impaired hepatic function, or severe renal\n             dysfunction\n\n          -  Have a condition or be in a situation that, in the Investigator's opinion, may put\n             the subject at significant risk, may confound the study results, or may interfere\n             significantly with the subject's participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680497", 
            "org_study_id": "MAF/AGN/MED/FIL/018"
        }, 
        "intervention": {
            "arm_group_label": "JUV\u00c9DERM VOLIFT\u2122", 
            "description": "All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use.  Up to 3 treatments will be administered:  Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.", 
            "intervention_name": "Crosslinked hyaluronic acid dermal filler", 
            "intervention_type": "Device", 
            "other_name": "JUV\u00c9DERM VOLIFT\u2122"
        }, 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koln", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naarden", 
                        "country": "Netherlands"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Allergan Medical", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Investigator assessment of nasolabial fold severity using the 5-point NLFSS (nasolabial fold severity scale)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "removed_countries": {
            "country": "Belgium"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680497"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}